Please find attached our intimation on captioned subject.

Net loss reportedResults restatedExceptional itemEmphasis of matterRevenue declinedResults View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹732.10

prior close

₹706.80

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-5.8% vs market

Pharmaceuticals peers, median of 165sector+0.2%-5.3% vs sector

On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+0.0

15m

+0.6

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.7-5.8+0.2-5.3

Next day

-10.5+0.7-11.2-0.1-10.4

-11.6+0.0-11.7-0.3-11.3

-12.4-1.1-11.3-1.3-11.0

-13.1+0.0-13.1-1.2-11.9

-15.0+0.3-15.3-1.5-13.5

-14.0+1.1-15.1-0.6-13.4

15d

-11.8+4.9-16.6-0.3-11.5

-7.3+5.3-12.7+3.1-10.4

-6.7+6.9-13.6+4.1-10.8

+14.6+11.9+2.7+7.1+7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs reported FY26 standalone revenue of Rs 179,755.17 lakhs, marginally up from Rs 177,135.18 lakhs in FY25. However, profit after tax dropped significantly to Rs 17,620.20 lakhs from Rs 25,734.88 lakhs, representing a 31.5% decline. The company recognized an exceptional item of Rs 279.49 lakhs due to new labour codes impact. Finance costs nearly doubled to Rs 4,690.08 lakhs from Rs 2,563.33 lakhs. The auditors issued an unmodified (clean) opinion, though they included an Emphasis of Matter regarding a foreign exchange derivative contract that was inadvertently excluded from fair value calculations in prior periods, resulting in Q3 FY26 figures being restated with a net impact of Rs 2,224.71 lakhs recognized in FY26. The Board declared a final dividend of Rs 2 per share.

Likely market impact

The 31.5% PAT decline despite flat revenue signals margin pressure from higher finance costs and forex losses. The derivative restatement and exceptional items are negatives, though the clean audit opinion provides some comfort. The stock may face pressure given the significant earnings contraction.